IPH62/NKp46 NKCEs binds to one or two antigens at the surface of tumor cells, and engage both CD16 and NKp46 activating receptors on NK cells. The co-engagement of NKp46 synergizes with CD16 to induce full NK cell activation and tumor cell lysis. Further, NKp46 expression is often conserved on infiltrating NK cells in most solid tumors.

NKp46 NKCE: design and Mechanism of action

Video microscopy: NKp46 NKCE

In the scope of the expanded oncology R&D collaboration announced in October 2018, AstraZeneca has acquired an option to exclusively license a multi-specific NKp46 NK cell engager from Innate Pharma preclinical portfolio.

Publications, posters and presentations